Protalix AI Stock Analysis
Want to see PLX full AI Analyst Report?
Protalix (PLX) AI Stock Analysis
Protalix
(NYSE MKT:PLX)
The score is driven primarily by the strong TTM profitability, improved cash generation, and a healthier balance sheet. Technicals support the trend (price above key moving averages and positive MACD) but are tempered by an elevated RSI that signals near-term froth. Valuation looks reasonable on a ~12x P/E, while the earnings call was constructive but constrained by higher spending, program timing uncertainty, and the lack of current guidance.
Protalix (PLX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $257.17M
- Dividend Yield
- ―
- Average Volume (3M)
- 855.31K
- Price to Earnings (P/E)
- 11.7
- Beta (1Y)
- 1.11
- Revenue Growth
- 36.96%
- EPS Growth
- 266.67%
- Country
- US
- Employees
- 226
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Protalix Business Overview & Revenue Model
Company Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Ele...
How the Company Makes Money
Protalix makes money primarily through (1) sales of its commercial products where it is the marketing authorization holder and sells product (with economics that may include revenue-sharing or profit-sharing depending on jurisdiction and partner arra...
Protalix Earnings Call Summary
The call was broadly positive, supported by strong nine-month revenue growth, higher quarterly revenue and net income, increasing Elfabrio sales and European penetration, a stronger cash position with no debt or warrants, and encouraging PRX-115 data and Phase II progress. The main negatives were higher R&D and SG&A expenses, increased tax expense, lower Pfizer revenue related to prior manufacturing issues, the delayed PRX-119 decision, and the absence of current revenue guidance. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said it expects the increase in Chiesi revenue to continue and that the trend will continue, but “We're not going to provide guidance now”; it will provide guidance for 2027 once it publishes annual results. The RELEASE study is actively enrolling, with top line results expected in the second half of next year, and expenses are expected to continue as the study and additional preclinical and clinical programs advance. Management expects to finalize Phase I enrollment next quarter, take a decision on PRX-119 this quarter and then clarify when it is planning to enter Phase I, while describing the 4-week Elfabrio dosing as a significant portion of patients and the first 9 months gross margin as a baseline. It also expects a good overall 2026 and plans to discuss future 2027 in mid-March.
Protalix Financial Statement Overview
Summary
Financials reflect a meaningful turnaround: TTM margins are strong (gross ~69%, operating ~31%, net ~23%), the balance sheet is de-risked with low leverage (debt-to-equity ~0.13) and strong ROE (~32%), and cash flow has improved to positive operating and free cash flow. The key offset is historical volatility in revenue and cash generation, which raises questions about durability.
Income Statement
78PositiveBalance Sheet
83Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.69M | 52.74M | 53.40M | 65.49M | 47.64M | 38.35M |
| Gross Profit | 60.31M | 25.24M | 29.08M | 42.51M | 28.05M | 22.00M |
| EBITDA | 28.56M | -2.95M | 6.52M | 12.94M | -10.78M | -18.94M |
| Net Income | 20.55M | -6.60M | 2.93M | 8.31M | -14.93M | -27.58M |
Balance Sheet | ||||||
| Total Assets | 118.24M | 82.35M | 73.42M | 84.43M | 55.79M | 73.67M |
| Cash, Cash Equivalents and Short-Term Investments | 48.54M | 30.27M | 34.83M | 44.56M | 22.18M | 38.98M |
| Total Debt | 9.14M | 8.32M | 5.53M | 27.69M | 33.47M | 33.47M |
| Total Liabilities | 37.69M | 34.12M | 30.21M | 50.87M | 66.43M | 79.70M |
| Stockholders Equity | 80.55M | 48.23M | 43.21M | 33.57M | -10.64M | -6.04M |
Cash Flow | ||||||
| Free Cash Flow | 15.06M | -13.63M | 7.39M | -2.47M | -25.63M | -11.74M |
| Operating Cash Flow | 17.56M | -11.99M | 8.67M | -1.32M | -25.00M | -10.29M |
| Investing Cash Flow | -14.34M | -2.37M | 4.22M | -16.71M | -5.04M | 18.92M |
| Financing Cash Flow | 4.88M | 9.33M | -16.79M | 24.67M | 8.24M | 12.08M |
Protalix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Positive. The current price of 3.05 is above the 20-day moving average (MA) of 2.66, above the 50-day MA of 2.69, and above the 200-day MA of 2.45, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 64.43 is Neutral, neither overbought nor oversold. The STOCH value of 86.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLX.
Protalix Risk Analysis
Protalix disclosed 64 risk factors in its most recent earnings report. Protalix reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksProtalix Peers Comparison
Overall Rating
- PLX77Outperform
IPHA52Neutral
SLS43Neutral
CHRS42Neutral
TARA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PLX | 77Outperform | $249.58M | 11.72 | 30.74% | ― | 36.96% | 266.67% |
| IPHA | 52Neutral | $163.27M | -2.35 | 152.56% | ― | -24.21% | 1.17% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SLS | 43Neutral | $1.62B | -39.56 | -31.95% | ― | ― | 30.50% |
| CHRS | 42Neutral | $83.22M | -0.54 | -239.55% | ― | -35.81% | 38.80% |
| TARA | 38Underperform | $150.23M | -1.81 | -46.15% | ― | ― | 4.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PLX | Protalix Biotherapeutics | 3.05 | 1.16 | 61.38% | |
| CHRS | Coherus Biosciences | 0.53 | -0.60 | -53.54% | |
| SLS | Sellas Life Sciences Group | 7.86 | 6.45 | 457.45% | |
| TARA | Protara Therapeutics, Inc. | 2.53 | -3.04 | -54.58% | |
| IPHA | Innate Pharma SA Sponsored ADR | 1.38 | -0.44 | -24.18% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026